睿知中国医院研究地图
候选清单

西安空军军医大学

空军军医大学西京医院

Xijing Hospital

在本站收录的 53 种疾病中,这家医院列在其中 26 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

空军军医大学西京医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文牵头 1 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma22 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma58 篇牵头论文
  4. 胃癌Stomach cancer62 篇牵头论文牵头 7 项开放试验
  5. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  6. 脊索瘤Chordoma1 篇牵头论文
  7. 骨肉瘤Osteosarcoma18 篇牵头论文
  8. 胃肠道间质瘤Gastrointestinal stromal tumour4 篇牵头论文
  9. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  10. 尤文肉瘤Ewing sarcoma2 篇牵头论文
  11. 多发性骨髓瘤Multiple myeloma2 篇牵头论文
  12. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia1 篇牵头论文
  13. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  14. IgG4相关性疾病IgG4-related disease1 篇牵头论文
  15. 烟雾病Moyamoya disease2 篇牵头论文
  16. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis3 篇牵头论文
  17. 大动脉炎Takayasu arteritis3 篇牵头论文
  18. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  19. 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
  20. 白塞病Behçet disease1 篇牵头论文
  21. IgA 肾病IgA nephropathy10 篇牵头论文
  22. 戈谢病Gaucher disease0 篇牵头论文
  23. 尼曼-匹克病 C 型Niemann–Pick disease type C1 篇牵头论文
  24. 原发性胆汁性胆管炎Primary biliary cholangitis17 篇牵头论文牵头 6 项开放试验
  25. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  26. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:视网膜母细胞瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、重症肌无力、肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、Alport 综合征、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 0020242025: 222025

西安有 2 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    GNT Induction Treatment in Locally Advanced NPC
    分期
    III期
    开始
    2023-09
    登记号
    NCT06026878

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院西安

  2. 正在招募
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    分期
    III期
    开始
    2022-04
    登记号
    NCT05340491

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

  3. 正在招募
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    分期
    III期
    开始
    2020-03
    登记号
    NCT03907826

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗技术影像与人工智能复发与转移
论文中的科室放疗科
牵头的论文5
  1. A novel multimodal adaptive delineation model for primary tumors and lymph node metastases in multi-center nasopharyngeal carcinoma radiotherapy.2025Computer methods and programs in biomedicine
  2. A predictive model based on the dosimetric parameters of the parotid stem cell region to assess the recovery of radiation-induced xerostomia in long-term survivors of nasopharyngeal carcinoma after radical radiotherapy.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  3. Therapeutic Evaluation of Induction Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma With Low-risk N Stage : A Multicenter Retrospective Study From Nonendemic Region of China.2023American journal of clinical oncology
  4. Prognostic analysis of 152 patients with distant metastasis after intensity-modulated radiotherapy for nasopharyngeal carcinoma.2021Annals of palliative medicine
  5. Detailed analysis of recovery process of cranial nerve palsy after IMRT-based comprehensive treatment in nasopharyngeal carcinoma.2021Radiation oncology (London, England)免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. GNT Induction Treatment in Locally Advanced NPC正在招募NCT06026878牵头方(推断)III期2023-09 启动
  2. GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China已完成NCT01596868牵头方(推断)II期2012-05 启动
  3. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial正在招募NCT05340491研究中心III期2022-04 启动
  4. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients正在招募NCT03907826研究中心III期2020-03 启动
  5. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma状态不明NCT03427827研究中心III期2018-07 启动
  6. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma状态不明NCT03700476研究中心III期2018-12 启动
PubMed 以外找到的论文(未计入)14
  1. Development and Validation of a Hybrid Clinical-Delta Radiomics Model to Predict Distant Metastasis after Definitive Radio-Chemotherapy in Non-Endemic Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physics论文
  2. Iron Metabolism in Nasopharyngeal Carcinoma: Multi-Omics Exploration of Tumor Progression, Immune Microenvironment, and Radiotherapy Efficacy2025International Journal of Radiation Oncology*Biology*Physics论文
  3. Zero-Cost Customized Oral Stents Reduce Setup Errors in Nasopharyngeal Cancer Radiotherapy: Secondary Analysis of a Randomized Trial2025International Journal of Radiation Oncology*Biology*Physics论文
  4. Gross Tumor Volume Auto Delineation Based on a Novel Multimodal Adaptive Segmentation Model in Multicenter Nasopharyngeal Carcinoma Radiotherapy2024International Journal of Radiation Oncology*Biology*Physics论文
  5. Mechanistic of RBM3 Regulating Rad51 Alternative Splicing Mediated DNA Damage Repair Promoting Radioresistance of Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文
  6. Prediction Study of Prognostic Nutrition Index on the Nausea and Vomiting of Patients with Cancer Undergoing Chemotherapy or Concurrent Chemoradiotherapy Based on Cisplatin2024International Journal of Radiation Oncology*Biology*Physics论文
  7. Development and Validation of CT-Based Dose-Volume-Radiomics Nomogram for Radiation Induced Hypothyroidism in Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physics论文
  8. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncology会议摘要
  9. RBM3 Induced Immune Resistance through Modulating Tumor Microenvironment in Nasopharyngeal Carcinoma2022International Journal of Radiation Oncology*Biology*Physics论文
  10. The Effects of Multidimensional Individualized Clinical Management (MDICM) in Radiotherapy for Patients with Head and Neck Cancer: A Pilot Study2022International Journal of Radiation Oncology*Biology*Physics论文
  11. Detailed analysis of recovery process of cranial nerve palsy after IMRT-based comprehensive treatment in nasopharyngeal carcinoma2021Research Square预印本
  12. Induction Chemotherapy Followed by Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy in T4N0-1M0 Patients With Nasopharyngeal Carcinoma: A Multicenter Retrospective Study2021International Journal of Radiation Oncology*Biology*Physics论文
  13. Mechanistic Study of Irradiated Dying NPC Cells Promoting the Metastatic Ability of Surviving NPC Cells After Radiotherapy2021International Journal of Radiation Oncology*Biology*Physics论文
  14. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.8%。

牵头论文
22
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 5520222023: 3320232024: 7720242025: 552025

西安有 5 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题放疗新辅助与综合治疗影像与人工智能
论文中的科室放疗科消化/肝病科病理/检验科
牵头的论文22
  1. Dual-Mode Radiosensitization of Esophageal Squamous Cell Carcinoma via SOCS6-Loaded Virus-Inspired Manganese-Bismuth Bimetallic Oxide Nanoparticles.2025Advanced healthcare materials
  2. Integration of machine learning in biomarker discovery for esophageal squamous cell carcinoma: Applications and future directions.2025Pathology, research and practice
  3. STC1 promotes esophageal squamous cell carcinoma progression and is associated with poor prognosis.2025Pathology, research and practice
  4. Impact of treatment time and waiting time on outcome for esophageal squamous cell carcinoma receiving definitive chemoradiotherapy.2025Radiation oncology (London, England)免费全文
  5. Comparison of radiation esophagitis associated with daytime versus evening radiotherapy in patients with esophageal carcinoma.2025Radiation oncology (London, England)免费全文
  6. RSK4 promotes the macrophage recruitment and M2 polarization in esophageal squamous cell carcinoma.2024Biochimica et biophysica acta. Molecular basis of disease
  7. Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma.2024Cancer biology & therapy免费全文
  8. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.2024Genome medicine免费全文
  9. A CT-based subregional radiomics nomogram for predicting local recurrence-free survival in esophageal squamous cell cancer patients treated by definitive chemoradiotherapy: a multicenter study.2024Journal of translational medicine免费全文
  10. Emerging role of cancer-associated fibroblasts in esophageal squamous cell carcinoma.2024Pathology, research and practice
  11. Long-term results of induction chemotherapy for non-operable esophageal squamous cell carcinoma followed by concurrent chemoradiotherapy: a single-centre experience.2024Radiology and oncology免费全文
  12. The diagnostic performance of V' and U' variables as an objective index of pink-color sign for diagnosing esophageal cancerous lesions.2024Surgical endoscopy
  13. Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma.2023Molecular cancer免费全文
  14. Re-irradiation for local primary-recurrence esophageal squamous cell carcinoma treated with IMRT/VMAT.2023Radiation oncology (London, England)免费全文
  15. Pre-procedure oral administration of pronase improves efficacy of lugol chromoendoscopy in esophageal squamous cell carcinoma screening: a prospective, double-blinded, randomized, controlled trial.2023Surgical endoscopyRCT
  16. Clinical benefit of tunnel endoscopic submucosal dissection for esophageal squamous cancer: a multicenter, randomized controlled trial.2022Gastrointestinal endoscopyRCT
  17. Comparing N-acetylcysteine with sodium thiosulfate for relieving symptoms caused by Lugol's iodine chromoendoscopy: a randomized, double-blind trial.2022Gastrointestinal endoscopyRCT
  18. Cancer stem cells in esophageal squamous cell carcinoma.2022Pathology, research and practice
  19. Overexpression of OTX1 promotes tumorigenesis in patients with esophageal squamous cell carcinoma.2022Pathology, research and practice
  20. CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: A multicenter study.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  21. Inhibition of SOCS6 confers radioresistance in esophageal squamous cell carcinoma.2021Biochemical and biophysical research communications
  22. Polygalacin D suppresses esophageal squamous cell carcinoma growth and metastasis through regulating miR-142-5p/Nrf2 axis.2021Free radical biology & medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy已完成NCT06063941牵头方不分期2023-10 启动
  2. DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer状态不明NCT05050760牵头方不分期2021-09 启动
  3. The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy已完成NCT04764643牵头方不分期2020-02 启动
  4. Efficacy and Safety of Endoscopic Submucosal Tunnel Dissection for Superficial Esophageal Squamous Cell Carcinoma已完成NCT03404921牵头方不分期2018-01 启动
  5. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
  6. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
  7. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma状态不明NCT01232374研究中心II期2010-09 启动
PubMed 以外找到的论文(未计入)14
  1. A Longitudinal CT-Based Subregional Radiomics Nomogram for Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy: A Multicenter Study2025International Journal of Radiation Oncology*Biology*Physics论文
  2. KDM6B Promotes the Development, Progression and Metastasis of Oesophageal Cancer through Demethylation of Histones in the LDHA Promoter Region2025Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agents论文
  3. Comparison of Anlotinib and S-1 Combined with Radiotherapy in the Treatment of Elderly Patients with Inoperable Esophageal Squamous Cell Cancer: An Open-Label, Phase 2, Randomized Controlled Trial2024International Journal of Radiation Oncology*Biology*Physics论文
  4. Comparison of Radiation Esophagitis Associated with Morning vs. Evening Radiotherapy in Patients with Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文
  5. Dolgoročni rezultati zdravljenja z indukcijsko kemoterapijo pri neoperabilnem ploščatoceličnem karcinomu požiralnika, ki ji je sledila sočasna kemoradioterapija2024DiRROS repository (University of Maribor)论文
  6. Longitudinal CT Feature-Based Model for Predicting Local Recurrence Free Survival in Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: A Multicenter Study2024International Journal of Radiation Oncology*Biology*Physics论文
  7. Value of Peritumoral Radiomics in Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Receiving Definitive (Chemo)Radiotherapy2024International Journal of Radiation Oncology*Biology*Physics论文
  8. Clinical-Radiomics Nomogram for Risk Prediction of Esophageal Fistula in Patients with Esophageal Squamous Cell Carcinoma Treated by IMRT or VMAT2023International Journal of Radiation Oncology*Biology*Physics论文
  9. Effect of system analysis of reactive oxygen species on prognosis and treatment decisions for patients with esophageal squamous carcinoma.2023Journal of Clinical Oncology会议摘要
  10. Long-Term Results of Induction Chemotherapy for Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy2023International Journal of Radiation Oncology*Biology*Physics论文
  11. Re-Irradiation for Locally Primary Recurrence in Esophageal Squamous Cell Carcinoma Treated with IMRT/VMAT2023International Journal of Radiation Oncology*Biology*Physics论文
  12. Cortactin Expression Identifies Invasion Depth in Superficial Esophageal Squamous Cell Carcinoma2022SSRN Electronic Journal预印本
  13. Correction: Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals2021Oncotarget勘误
  14. Long-Term Clinical Outcome and Safety Analysis of Superficial Esophageal Cancer Patients Receiving Definite or Adjuvant/Salvage Radiotherapy2021International Journal of Radiation Oncology*Biology*Physics论文

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 58 篇,占 0.4%。

牵头论文
58
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 141420222023: 9920232024: 101020242025: 15152025

西安有 4 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室普外/肝胆胰外科消化/肝病科肿瘤内科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文58
  1. A deep learning-based psi CT network effectively predicts early recurrence after hepatectomy in HCC patients.2025Abdominal radiology (New York)
  2. Surveillance and management of hepatocellular carcinoma after treatment of hepatitis C with direct-acting antiviral drugs.2025Annals of hepatology
  3. SLC25A35 enhances fatty acid oxidation and mitochondrial biogenesis to promote the carcinogenesis and progression of hepatocellular carcinoma by upregulating PGC-1α.2025Cell communication and signaling : CCS免费全文
  4. The Hippo-YAP signaling pathway promotes hepatocellular carcinoma progression by inducing FHL3 expression.2025Cell death & disease免费全文
  5. Cellular Membrane Protein GRINA is Highly Expressed and Associated with Survival Outcomes in Liver Cancer Patients.2025Current medical science
  6. The oncogenic role of BCL2L12 associated with immune status in the prognosis of human hepatocellular carcinoma.2025Die Naturwissenschaften
  7. Targeting METTL8 with Rabdosiin overcomes lenvatinib resistance in hepatocellular carcinoma.2025Experimental cell research
  8. Intratumoral bacterial load and tertiary lymphoid structure density in hepatocellular carcinoma: association and prognostic significance.2025Frontiers in immunology免费全文
  9. ASPM mediates nuclear entrapment of FOXM1 via liquid-liquid phase separation to promote progression of hepatocarcinoma.2025Genome biology免费全文
  10. DDX17-Mediated Upregulation of CXCL8 Promotes Hepatocellular Carcinoma Progression via Co-activating β-catenin/NF-κB Complex.2025International journal of biological sciences免费全文
  11. CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma.2025Journal of hepatology
  12. Prognostic model development using novel genetic signature associated with adenosine metabolism and immune status for patients with hepatocellular carcinoma.2025Journal of physiology and biochemistry免费全文
  13. Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma.2025Molecular cancer免费全文
  14. The Knockdown of USP34 Inhibits the Progression of Hepatocellular Carcinoma by Accelerating c-Myc Degradation.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  15. Performance of Ultrasonography-Based Fractal Parameters in Distinguishing Hepatocellular Carcinoma From Intrahepatic Cholangiocarcinoma.2025Ultrasonic imaging
  16. Constructing a disulfidptosis-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing and weighted co-expression network analysis.2024Apoptosis : an international journal on programmed cell death
  17. Identification of RCAN1's role in hepatocellular carcinoma using single-cell analysis.2024BMC cancer免费全文
  18. Development of a Novel CD8+ T Cell-Associated Signature for Prognostic Assessment in Hepatocellular Carcinoma.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  19. Targeting autophagy in HCC treatment: exploiting the CD147 internalization pathway.2024Cell communication and signaling : CCS免费全文
  20. Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Ultrasound-guided Microwave Ablation.2024Current medical imaging
  21. Clinical Characteristics and Prognosis of Early-Onset Hepatocellular Carcinoma: A Retrospective Cohort Study Based on Population Data.2024Digestive diseases and sciences
  22. Long-term survival analysis of ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma conforming to the Milan criteria: primary versus recurrent HCC.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  23. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.2024Medical oncology (Northwood, London, England)
  24. Early versus Late Recurrence of Hepatocellular Carcinoma after Microwave Ablation: Patterns, Treatments, and Post-Recurrence Survival.2024Oncology
  25. CCDC58 is a potential biomarker for diagnosis, prognosis, immunity, and genomic heterogeneity in pan-cancer.2024Scientific reports免费全文
  26. The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP.2023Cancer letters
  27. Peritumor tertiary lymphoid structures are associated with infiltrating neutrophils and inferior prognosis in hepatocellular carcinoma.2023Cancer medicine免费全文
  28. Downregulated mitochondrial transcription factor A enhances mycoplasma infection to promote the metastasis of hepatocellular carcinoma.2023Cancer science免费全文
  29. Different 18F-FDG imaging: A rare case of liver multiple carcinomas.2023Clinics and research in hepatology and gastroenterology
  30. ASRGL1 downregulation suppresses hepatocellular carcinoma tumorigenesis in a CDK1-dependent manner.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  31. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.2023Journal of experimental & clinical cancer research : CR免费全文
  32. N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment.2023Journal of gastroenterology
  33. HMGB1-mediated elevation of KLF7 facilitates hepatocellular carcinoma progression and metastasis through upregulating TLR4 and PTK2.2023Theranostics免费全文
  34. Targeting β-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma.2023Theranostics免费全文
  35. Mitochondrial fission factor promotes cisplatin resistancein hepatocellular carcinoma.2022Acta biochimica et biophysica Sinica免费全文
  36. Galectin-9 expression predicts poor prognosis in hepatitis B virus-associated hepatocellular carcinoma.2022Aging免费全文
  37. Tubulin-binding peptide RR-171 derived from human umbilical cord serum displays antitumor activity against hepatocellular carcinoma via inducing apoptosis and activating the NF-kappa B pathway.2022Cell proliferation免费全文
  38. Low Expression of Phosphodiesterase 2 (PDE2A) Promotes the Progression by Regulating Mitochondrial Morphology and ATP Content and Predicts Poor Prognosis in Hepatocellular Carcinoma.2022Cells免费全文
  39. Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.2022Current oncology (Toronto, Ont.)免费全文
  40. A Novel Oxidative Phosphorylation-Associated Gene Signature for Prognosis Prediction in Patients with Hepatocellular Carcinoma.2022Disease markers免费全文
  41. Prognostic Significance of CCDC137 Expression and Its Association with Immune Infiltration in Hepatocellular Carcinoma.2022Disease markers免费全文
  42. Tertiary lymphoid structures: Associated multiple immune cells and analysis their formation in hepatocellular carcinoma.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  43. Overexpression of SLC25A51 promotes hepatocellular carcinoma progression by driving aerobic glycolysis through activation of SIRT5.2022Free radical biology & medicine
  44. Protective effect of tertiary lymphoid structures against hepatocellular carcinoma: New findings from a genetic perspective.2022Frontiers in immunology免费全文
  45. Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma.2022Frontiers in immunology免费全文
  46. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  47. A novel immune checkpoint-related gene signature for hepatocellular carcinoma to predict clinical outcomes and therapeutic response.2022Mathematical biosciences and engineering : MBE
  48. m6A-Related Angiogenic Genes to Construct Prognostic Signature, Reveal Immune and Oxidative Stress Landscape, and Screen Drugs in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevity免费全文
  49. Potentiality of α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) in prognosis prediction and immunotherapy response for patients with hepatocellular carcinoma.2021Bioengineered免费全文
  50. Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments.2021Cancer science免费全文
  51. Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation.2021Cell death & disease免费全文
  52. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.2021Gut免费全文
  53. Increased expression of Cyclin F in liver cancer predicts poor prognosis: A study based on TCGA database.2021Medicine免费全文
  54. Total flavonoids of Radix Tetrastigma suppress inflammation-related hepatocellular carcinoma cell metastasis.2021Molecular genetics and genomics : MGG免费全文
  55. Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway.2021Scientific reports免费全文
  56. Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers.2021Signal transduction and targeted therapy免费全文
  57. Circulating tumour DNA methylation in hepatocellular carcinoma diagnosis using digital droplet PCR.2021The Journal of international medical research免费全文
  58. Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy.2021Theranostics免费全文
中文论文(未计入)2
  1. [Prediction of immune-related genes associated with prognosis in patients with hepatocellular carcinoma by bioinformatics methods].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  2. [T cell factor 3 (TCF3) is overexpressed in hepatocellular carcinoma and promotes their invasion and metastasis].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma状态不明NCT03993743牵头方I期2019-05 启动
  2. Exploration of Noninvasive Differential Diagnosis of Benign and Malignant Liver Tumors状态不明NCT06524557牵头方2018-01 启动
  3. Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis状态不明NCT01201655牵头方2010-01 启动
  4. Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)状态不明NCT03969576牵头方(推断)不分期2020-09 启动
  5. TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma状态不明NCT02529761牵头方(推断)不分期2015-08 启动
  6. Sorafenib Chemoembolization Evaluation Controlled Trial已完成NCT01906216牵头方(推断)III期2013-09 启动
  7. Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function已完成NCT06245785研究中心2023-01 启动
  8. Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension已完成NCT06245798研究中心2023-01 启动
  9. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)已完成NCT02112656研究中心III期2014-06 启动
  10. Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC状态不明NCT02018757研究中心II期2014-01 启动
  11. Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma状态不明NCT02418988研究中心II期2014-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 62 篇,占 0.6%。

牵头论文
62
2021–2025 年
牵头试验
27
任何状态,ClinicalTrials.gov
牵头的开放试验
7
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 9920222023: 161620232024: 7720242025: 21212025

西安有 5 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time
    分期
    不分期
    开始
    2026-03
    登记号
    NCT07401303

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院西安

  2. 正在招募
    Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07600125

    年龄 18 岁 至 未注明(登记的条件)

    牵头:空军军医大学西京医院;另有 3 家列出的医院为研究中心大连、无锡、西安、青岛

  3. 正在招募
    A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
    分期
    II期
    开始
    2026-07
    登记号
    NCT07788196

    年龄 18 岁 至 未注明(登记的条件)

    牵头:空军军医大学西京医院西安

  4. 正在招募
    Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
    分期
    未注明
    开始
    2025-05
    登记号
    NCT06979895

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 1 家列出的医院为研究中心西安

  5. 正在招募
    The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
    分期
    未注明
    开始
    2023-08
    登记号
    NCT05956847

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:空军军医大学西京医院西安

  6. 即将招募
    Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
    分期
    II期
    开始
    2026-07
    登记号
    NCT07685704

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院西安

  7. 即将招募
    Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
    分期
    不分期
    开始
    2025-06
    登记号
    NCT07014254

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:空军军医大学西京医院西安

  8. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  9. 正在招募
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    分期
    不分期
    开始
    2024-09
    登记号
    NCT06128252

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 11 家列出的医院为研究中心上海、乌鲁木齐、南京、武汉、沈阳、西安、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期早期发现与内镜手术
论文中的科室消化/肝病科病理/检验科普外/肝胆胰外科影像/核医学科
牵头的论文62
  1. Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer: The Largest Systematic Reviews of 68,755 Patients and Meta-analysis.2025Annals of surgical oncology
  2. Comparison of short- and long-term outcomes among total laparoscopic, laparoscopic-assisted, and open total gastrectomies for advanced gastric cancer patients after neoadjuvant chemotherapy: a multicenter retrospective cohort study.2025BMC cancer免费全文
  3. Impact of anastomotic orientation (Upward vs. Downward) in Roux-en-Y reconstruction on duodenal stump leakage incidence after radical total gastrectomy: a retrospective comparative study.2025BMC cancer免费全文
  4. Short- and long-term outcomes of robotic- versus laparoscopic-assisted early-onset gastric cancer: a propensity score-matched retrospective cohort study.2025BMC cancer免费全文
  5. A prospective randomized study of the efficacy of continuous active warming in patients undergoing laparoscopic gastrectomy.2025BMC gastroenterologyRCT免费全文
  6. Extracellular vesicle-derived lncRNA-GC1 serves as a novel biomarker for predicting and monitoring the immunotherapeutic outcomes of patients with gastric cancer.2025BMC medicine免费全文
  7. Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies.2025Biochimica et biophysica acta. Reviews on cancer
  8. FXYD5 regulates gastric cancer cell metastasis and drug resistance by EMT modulation.2025Cancer gene therapy
  9. Evaluating the prognostic significance of tumor deposits in gastric cancer and strategies for their integration into the TNM staging system: a single-center retrospective study.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  10. A Novel Prognostic Risk Model Based on Oxidative Stress to Predict Survival and Improve Treatment Strategies in Stomach Adenocarcinoma.2025Combinatorial chemistry & high throughput screening
  11. The proteomic and transcriptomic profiles of gastric mucosa from health volunteers.2025Computers in biology and medicine
  12. Diagnostic efficacy of an extracellular vesicle-derived lncRNA-based liquid biopsy signature for the early detection of early-onset gastric cancer.2025Gut
  13. Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer.2025International journal of surgery (London, England)RCT免费全文
  14. Prediction of a Panel of Programmed Cell Death Protein-1 (PD-1) Inhibitor-Sensitive Biomarkers Using Multiphase Computed Tomography Imaging Textural Features: Retrospective Cohort Analysis.2025JMIR cancer免费全文
  15. UPP1/ARNT positive feedback loop drives gastric cancer progression through metabolism reprogramming.2025Medical oncology (Northwood, London, England)
  16. Interaction of PHGDH with IGF2BP1 facilitates m6A-dependent stabilization of TCF7L2 mRNA to confer multidrug resistance in gastric cancer.2025Oncogene
  17. The Fritillaria alkaloid peiminine acts as a chemosensitizer to potentiate oxaliplatin efficacy against gastric cancer.2025Pathology, research and practice
  18. Discovery of KMT5A repressed miR-99b cluster with potential to restore chemotherapy sensitivity in gastric cancer by regulating mitochondrial complex II and affecting OXPHOS.2025Pharmacological research
  19. The progression rate and risk factor analysis of small gastric subepithelial tumors: a systematic review and meta-analysis.2025Surgical endoscopy
  20. Platinum drugs upregulate CXCR4 and PD-L1 expression via ROS-dependent pathways, with implications for novel combined treatment in gastric cancer.2025The journal of pathology. Clinical research免费全文
  21. Comparison of the efficacy of TissuePatch™ versus no TissuePatch™ to seal pancreatic tissue surface for the prevention of pancreatic fistula after radical gastrectomy: study protocol for a prospective, single-center, randomized controlled t2025Trials免费全文
  22. N6-methyladenosine reader hnRNPA2B1 recognizes and stabilizes NEAT1 to confer chemoresistance in gastric cancer.2024Cancer communications (London, England)免费全文
  23. YTHDC1 promotes the malignant progression of gastric cancer by promoting ROD1 translocation to the nucleus.2024Cell biology and toxicology免费全文
  24. Biological functions of Circular RNA_LARP4/ Upstream frameshift 1 in development of gastric cancer.2024Cellular and molecular biology (Noisy-le-Grand, France)
  25. Emerging trends in early-onset gastric cancer.2024Chinese medical journal免费全文
  26. Analysis of Risk Factors for Gastric Cancer and Precancerous Lesions: A Case-Control Study.2024Journal of digestive diseases免费全文
  27. The inflammation score predicts the prognosis of gastric cancer patients undergoing Da Vinci robot surgery.2024Journal of robotic surgery
  28. miR-107 reverses the multidrug resistance of gastric cancer by targeting the CGA/EGFR/GATA2 positive feedback circuit.2024The Journal of biological chemistry免费全文
  29. Log odds of positive lymph nodes as a novel prognostic predictor for gastric cancer: a systematic review and meta-analysis.2023BMC cancer免费全文
  30. Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer.2023Cancer communications (London, England)免费全文
  31. Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer.2023Cancer medicine免费全文
  32. Cancer associated fibroblast derived SLIT2 drives gastric cancer cell metastasis by activating NEK9.2023Cell death & disease免费全文
  33. MG7-Ag, hTERT, and TFF2 identified high-risk intestinal metaplasia and constituted a prediction model for gastric cancer.2023Chinese medical journal免费全文
  34. Identification and validation of a novel prognostic circadian rhythm-related gene signature for stomach adenocarcinoma.2023Chronobiology international
  35. E3 ubiquitin ligase RNF180 prevents excessive PCDH10 methylation to suppress the proliferation and metastasis of gastric cancer cells by promoting ubiquitination of DNMT1.2023Clinical epigenetics免费全文
  36. DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS/MEK/ERK activity in gastric cancer cells.2023Epigenetics免费全文
  37. Development and validation of a ligand-receptor pairs signature to predict outcome and provide a therapeutic strategy in gastric cancer.2023Expert review of molecular diagnostics
  38. Sintilimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel regimen as neoadjuvant therapy for resectable gastric cancer and biomarker exploration.2023Future oncology (London, England)
  39. A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.2023Gastroenterology
  40. Relationship between gastric xanthoma, gastric precancerous lesions, and gastric cancer: A retrospective study.2023Journal of digestive diseases
  41. Endoscopic grading of gastric atrophy and histological gastritis staging on risk assessment for early gastric cancer: A case-control study.2023Journal of digestive diseases
  42. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.2023Journal of translational medicine免费全文
  43. Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer.2023Oncogene免费全文
  44. Comparing intracorporeal mechanical anastomosis vs. hand-sewn esophagojejunostomy after total laparoscopic gastrectomy for esophagogastric junction cancer: a single-center study.2023World journal of surgical oncology免费全文
  45. Rho GTPase-activating protein 35 suppresses gastric cancer metastasis by regulating cytoskeleton reorganization and epithelial-to-mesenchymal transition.2022Bioengineered免费全文
  46. Sec62 promotes gastric cancer metastasis through mediating UPR-induced autophagy activation.2022Cellular and molecular life sciences : CMLS免费全文
  47. Bile reflux and bile acids in the progression of gastric intestinal metaplasia.2022Chinese medical journal免费全文
  48. Circulating exosomal gastric cancer-associated long noncoding RNA1 as a noninvasive biomarker for predicting chemotherapy response and prognosis of advanced gastric cancer: A multi-cohort, multi-phase study.2022EBioMedicine免费全文
  49. Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer.2022Frontiers in immunology免费全文
  50. MiR-585-5p impedes gastric cancer proliferation and metastasis by orchestrating the interactions among CREB1, MAPK1 and MITF.2022Frontiers in immunology免费全文
  51. E2F1-mediated up-regulation of TOP2A promotes viability, migration, and invasion, and inhibits apoptosis of gastric cancer cells.2022Journal of biosciences
  52. Effects of mRNA expression of five Notch ligands on prognosis of gastric carcinoma.2022Scientific reports免费全文
  53. A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer.2022The Journal of clinical investigation免费全文
  54. Total Laparoscopic Uncut Roux-en-Y for Radical Distal Gastrectomy: An Interim Analysis of a Randomized, Controlled, Clinical Trial.2021Annals of surgical oncologyRCT
  55. Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas.2021Cancer biology & medicine免费全文
  56. Is intestinal metaplasia the point of no return in the progression of gastric carcinogenesis?2021Chinese medical journal免费全文
  57. Circular RNA PTK2 Accelerates Cell Proliferation and Inhibits Cell Apoptosis in Gastric Carcinoma via miR-139-3p.2021Digestive diseases and sciences
  58. HDAC6/HNF4α loop mediated by miR-1 promotes bile acids-induced gastric intestinal metaplasia.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  59. Bile reflux is an independent risk factor for precancerous gastric lesions and gastric cancer: An observational cross-sectional study.2021Journal of digestive diseases免费全文
  60. Impact of Laparoscopic Converted to Open Gastrectomy on Short- and Long-Term Outcomes of Patients with Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  61. Resveratrol inhibits bile acid-induced gastric intestinal metaplasia via the PI3K/AKT/p-FoxO4 signalling pathway.2021Phytotherapy research : PTR免费全文
  62. NEK9, a novel effector of IL-6/STAT3, regulates metastasis of gastric cancer by targeting ARHGEF2 phosphorylation.2021Theranostics免费全文
中文论文(未计入)8
  1. [Gastrointestinal hamartomatous inverted hyperplastic polyps: a clinicopathological analysis of ten cases].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Visualizing the evidence of robotic gastrointestinal surgery based on guideline recommendations: an evidence mapping study of gastric and colorectal cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Comparison of short-term safety and efficacy among total laparoscopic, laparoscopy-assisted, and open radical total gastrectomy after neoadjuvant therapy: a multicenter retrospective study].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [The correlation between No. 6 and No. 14v lymph node metastasis and the value of dissecting these lymph nodes in radical gastrectomy].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [N6-methyladenosine (m6A) binding protein hnRNPA2B1 is highly expressed in a variety of tumors and regulates tumor immune microenvironment].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  6. [Patient experience in the implementation of enhanced recovery after surgery strategy after radical gastric cancer surgery].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Management of anastomotic leakage after laparoscopic surgery for adenocarcinoma of esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Functional evaluation after function-preserving gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)37
  1. Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers正在招募NCT07600125牵头方2026-08 启动
  2. Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time正在招募NCT07401303牵头方不分期2026-03 启动
  3. A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.正在招募NCT07788196牵头方II期2026-07 启动
  4. Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer正在招募NCT06979895牵头方2025-05 启动
  5. Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies即将招募NCT07014254牵头方不分期2025-06 启动
  6. The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric正在招募NCT05956847牵头方2023-08 启动
  7. Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction进行中,不再招募NCT06576921牵头方II期2024-11 启动
  8. ERAS in Totally Laparoscopic Total Gastrectomy for Gastric Cancer状态不明NCT06489288牵头方不分期2024-05 启动
  9. Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer已完成NCT06031779牵头方2023-05 启动
  10. An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC状态不明NCT05800080牵头方不分期2023-04 启动
  11. Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology已完成NCT05742568牵头方IV期2022-12 启动
  12. A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions已完成NCT06282484牵头方2022-09 启动
  13. Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy已完成NCT04697186牵头方IV期2021-01 启动
  14. Early Diagnosis of Gastric Cancer Cachexia状态不明NCT06277986牵头方2021-06 启动
  15. A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication已完成NCT04660123牵头方IV期2020-12 启动
  16. Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies已完成NCT04209933牵头方IV期2020-05 启动
  17. Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer已完成NCT04660058牵头方2020-12 启动
  18. Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy已完成NCT04678492牵头方IV期2020-12 启动
  19. Study on the Effect of Bile Reflux on Gastric Cancer and Its Precancerous Lesions: a Cross-sectional Study.已完成NCT03976739牵头方2019-06 启动
  20. Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy已完成NCT03609892牵头方IV期2018-08 启动
  21. The Efficacy of Esomeprazole Premedication on Intraoperative Bleeding During Gastric ESD已完成NCT02730533牵头方不分期2016-03 启动
  22. The Feasible Research of Infrared Endoscope to Diagnose Early Gastric Cancer状态不明NCT02710838牵头方不分期2014-01 启动
  23. Comparison of O-type Hybrid Knife and IT Knife in ESD已完成NCT01760070牵头方不分期2012-12 启动
  24. Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study即将招募NCT07685704牵头方(推断)II期2026-07 启动
  25. Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer状态不明NCT06169410牵头方(推断)IV期2023-12 启动
  26. The Influence of Splenic Artery Characteristics in Gastric Cancer Surgery进行中,不再招募NCT06680362牵头方(推断)2022-05 启动
  27. Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer状态不明NCT05052931牵头方(推断)II期2021-10 启动
  28. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  29. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer正在招募NCT06128252研究中心不分期2024-09 启动
  30. Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing状态不明NCT06036563研究中心2023-09 启动
  31. Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA状态不明NCT05668910研究中心2022-09 启动
  32. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  33. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer状态不明NCT03273920研究中心不分期2017-09 启动
  34. Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy状态不明NCT03223740研究中心III期2016-09 启动
  35. Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy状态不明NCT02110628研究中心III期2014-08 启动
  36. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer已完成NCT01774786研究中心III期2013-06 启动
  37. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

西安有 5 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科普外/肝胆胰外科
牵头的论文1
  1. Mitochondrial fragmentation is crucial for c-Myc-driven hepatoblastoma-like liver tumors.2022Molecular therapy : the journal of the American Society of Gene Therapy
中文论文(未计入)1
  1. [Hepatoblastoma in elderly female: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

西安有 5 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 18 篇,占 0.8%。

牵头论文
18
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 3320222023: 6620232024: 3320242025: 112025

西安有 11 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科
牵头的论文18
  1. Curculigoside exhibits multiple therapeutic efficacy to induce apoptosis and ferroptosis in osteosarcoma via modulation of ROS and tumor microenvironment.2025Tissue & cell
  2. Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome.2024Cancer immunology, immunotherapy : CII
  3. The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient-Derived Xenografts and Next-Generation Sequencing.2024Cancer medicine
  4. A deep learning model for accurately predicting cancer-specific survival in patients with primary bone sarcoma of the extremity: a population-based study.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  5. Characterization of myeloid signature genes for predicting prognosis and immune landscape in Ewing sarcoma.2023Cancer science
  6. Deciphering the heterogeneity and immunosuppressive function of regulatory T cells in osteosarcoma using single-cell RNA transcriptome.2023Computers in biology and medicine
  7. Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma.2023International immunopharmacology
  8. Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study.2023Journal of cancer research and therapeutics
  9. A classification system of joint-salvage tumor resection in osteosarcoma of the knee: A retrospective cohort study.2023The Knee
  10. Does joint-sparing tumor resection jeopardize oncologic and functional outcomes in non-metastatic high-grade osteosarcoma around the knee?2023World journal of surgical oncology
  11. Is the Capanna Technique a Reliable Method for Revision Surgery after Failure of Previous Limb-Salvage Surgery?2022Annals of surgical oncology
  12. Intercalary tibial reconstruction with frozen tumor-bearing autograft in combination with ipsilateral fibula in limb-salvage surgery.2022Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  13. Lateral Malleolus Reconstruction After Tumor Resection in Children: A Case Report and Literature Review.2022Orthopaedic surgery
  14. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review.2021Annals of palliative medicine
  15. Use of Vascularized Fibular Epiphyseal Transfer with Massive Bone Allograft for Proximal Humeral Reconstruction in Children with Bone Sarcoma.2021Annals of surgical oncology
  16. Prognostic value of tumoral and peritumoral magnetic resonance parameters in osteosarcoma patients for monitoring chemotherapy response.2021European radiology
  17. The Synergistic Reducing Drug Resistance Effect of Cisplatin and Ursolic Acid on Osteosarcoma through a Multistep Mechanism Involving Ferritinophagy.2021Oxidative medicine and cellular longevity
  18. Cryoablation-aided joint retention surgery for epiphysis involvement in osteosarcoma compared with endoprosthetic replacement.2021The bone & joint journal
早期论文(2016–2020 年)8
  1. Primary Osteosarcoma of the Liver: Case Report and Literature Review.2020Pathology oncology research : POR
  2. Factors Influencing Osseous Union Following Surgical Treatment of Bone Tumors with Use of the Capanna Technique.2019The Journal of bone and joint surgery. American volume
  3. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.2018Journal of experimental & clinical cancer research : CR
  4. Honokiol induces autophagy and apoptosis of osteosarcoma through PI3K/Akt/mTOR signaling pathway.2018Molecular medicine reports
  5. What are the Oncologic and Functional Outcomes After Joint Salvage Resections for Juxtaarticular Osteosarcoma About the Knee?2017Clinical orthopaedics and related research
  6. [Detection and clinical significance of circulating tumor cells in osteosarcoma using immunofluorescence combined with in situ hybridization].2017Zhonghua zhong liu za zhi [Chinese journal of oncology]
  7. Extracorporeally frozen tumour-bearing bone combined with free vascularised fibula for the intercalary reconstruction of femoral defect after resection of bony sarcoma.2016Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  8. Preliminary Application of Precision Genomic Medicine Detecting Gene Variation in Patients with Multifocal Osteosarcoma.2016Orthopaedic surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma状态不明NCT01002092研究中心II期2009-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025

西安有 3 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文4
  1. Regulatory roles of non-coding RNAs in programmed cell death pathways and drug resistance in gastrointestinal stromal tumors.2025Clinical and experimental medicine
  2. An interpretable machine learning framework for automated mitosis detection in gastrointestinal stromal tumors.2025Pathology, research and practice
  3. The progression rate and risk factor analysis of small gastric subepithelial tumors: a systematic review and meta-analysis.2025Surgical endoscopy
  4. Development and validation of a prognostic nomogram for gastrointestinal stromal tumors in the postimatinib era: A study based on the SEER database and a Chinese cohort.2023Cancer medicine
早期论文(2016–2020 年)14
  1. Current characteristics on small intestinal stromal tumor-a case control study.2020Annals of palliative medicine
  2. A multivariate prediction model for high malignancy potential gastric GI stromal tumors before endoscopic resection.2020Gastrointestinal endoscopy
  3. Genetic alterations in cell cycle regulation-associated genes may promote primary progression of gastrointestinal stromal tumors.2020Laboratory investigation; a journal of technical methods and pathology
  4. Clinicopathological Features and Prognosis of Gastrointestinal Stromal Tumor Located in the Jejunum and Ileum.2019Digestive surgery
  5. Clinicopathological features, surgical strategy and prognosis of duodenal gastrointestinal stromal tumors: a series of 300 patients.2018BMC cancer
  6. Meta-analysis comparing laparoscopic versus open resection for gastric gastrointestinal stromal tumors larger than 5 cm.2017BMC cancer
  7. Pancreatic Gastrointestinal Stromal Tumor: Clinicopathologic Features and Prognosis.2017Journal of clinical gastroenterology
  8. Clinicopathological features and prognosis of mesenteric gastrointestinal stromal tumor: evaluation of a pooled case series.2017Oncotarget
  9. Clinicopathological feature and prognosis of primary hepatic gastrointestinal stromal tumor.2016Cancer medicine
  10. Clinicopathological features and prognosis of coexistence of gastric gastrointestinal stromal tumor and gastric cancer.2016Medicine
  11. Combination of PLR, MLR, MWR, and Tumor Size Could Significantly Increase the Prognostic Value for Gastrointestinal Stromal Tumors.2016Medicine
  12. Clinicopathologic Features and Clinical Outcomes of Esophageal Gastrointestinal Stromal Tumor: Evaluation of a Pooled Case Series.2016Medicine
  13. Clinicopathological features and prognosis of colonic gastrointestinal stromal tumors: evaluation of a pooled case series.2016Oncotarget
  14. Clinicopathological features and prognosis of omental gastrointestinal stromal tumor: evaluation of a pooled case series.2016Scientific reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Exploring the Molecular Mechanism Based on KIT Mutation状态不明NCT05895942牵头方2021-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

西安有 12 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

西安有 4 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.1%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

西安有 4 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    分期
    未注明
    开始
    2026-06
    登记号
    NCT07663253

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属中山医院;另有 9 家列出的医院为研究中心上海、北京、南宁、南通、广州、成都、昆明、武汉、西安、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层肾脏与骨骼并发症
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

西安有 4 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。

这些数字背后的记录
研究主题干细胞移植费城染色体与遗传学

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

西安有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

西安有 1 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题胰腺与胆管
论文中的科室消化/肝病科
牵头的论文1
  1. Recent advances in IgG4-related autoimmune pancreatitis.2024Pathology, research and practice
中文论文(未计入)2
  1. [Analysis of clinical characteristics and current diagnosis and treatment status of IgG4-related diseases in the real world].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [IgG4-related diseases of the gastrointestinal tract].2025Zhonghua nei ke za zhi

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

西安有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题影像与脑血流血管重建手术
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025

西安有 3 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

西安有 3 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室影像/核医学科风湿免疫科
牵头的论文3
  1. Brain computed tomography perfusion alterations in patients with Takayasu arteritis with steno-occlusive carotid arteries: a retrospective study.2025Clinical rheumatology
  2. The establishment and validation of reference intervals for plasma Pentraxin-3 in healthy volunteers and patients with Takayasu's arteritis.2022Clinica chimica acta; international journal of clinical chemistry
  3. Acute myocardial infarction with left main coronary artery ostial negative remodelling as the first manifestation of Takayasu arteritis: a case report.2021BMC cardiovascular disorders
中文论文(未计入)1
  1. [Clinical features and CT findings of Takayasu's arteritis associated pulmonary hypertension].2021Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
早期论文(2016–2020 年)3
  1. Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu's arteritis patients.2020European journal of nuclear medicine and molecular imaging
  2. Contrast-enhanced Ultrasonography for Monitoring Arterial Inflammation in Takayasu Arteritis.2019The Journal of rheumatology
  3. [Association between platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with disease activity in Takayasu arteritis patients].2018Zhonghua xin xue guan bing za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis已完成NCT03096275研究中心III期2017-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

西安有 10 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

西安有 3 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

西安有 3 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 10 篇,占 1.4%。

牵头论文
10
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 3320222023: 1120232024: 2220242025: 002025

西安有 7 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
    分期
    III期
    开始
    2026-04
    登记号
    NCT07390123

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、临沂、北京、湛江、芜湖、西安、长春、长沙、黄山

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科
牵头的论文10
  1. Exploring the crosstalk molecular mechanisms between IgA nephropathy and Sjögren's syndrome based on comprehensive bioinformatics and immunohistochemical analyses.2024Clinical and experimental medicine
  2. Immune checkpoint activity exacerbate renal interstitial fibrosis progression by enhancing PD-L1 expression in renal tubular epithelial cells.2024Translational research : the journal of laboratory and clinical medicine
  3. Serum Long Noncoding RNA H19 and CKD Progression in IgA Nephropathy.2023Journal of nephrology
  4. Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria.2022Clinical and experimental nephrology
  5. The clinicopathological characteristics and outcomes of IgA nephropathy with predominant lambda or kappa light-chain deposition.2022International urology and nephrology
  6. Expansion of Escherichia-Shigella in Gut Is Associated with the Onset and Response to Immunosuppressive Therapy of IgA Nephropathy.2022Journal of the American Society of Nephrology : JASNRCT
  7. Low-Dose Corticosteroid Combined With Mycophenolate Mofetil for IgA Nephropathy With Stage 3 or 4 CKD: A Retrospective Cohort Study.2021Clinical therapeutics
  8. The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.2021Renal failure
  9. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports.2021Renal failure
  10. Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis.2021Renal failure
中文论文(未计入)1
  1. [Retrospective Analysis of the Effect of Uric Acid on the Prognosis of Immunoglobulin A Nephropathy With Stage 3-4 Chronic Kidney Disease].2023Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
早期论文(2016–2020 年)5
  1. A Comparative Study of the Gut Microbiota Associated With Immunoglobulin a Nephropathy and Membranous Nephropathy.2020Frontiers in cellular and infection microbiology
  2. Renal survival and risk factors in IgA nephropathy with crescents.2020International urology and nephrology
  3. Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria.2020International urology and nephrologyRCT
  4. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.2020Journal of nephrology
  5. The landscape and diagnostic potential of T and B cell repertoire in Immunoglobulin A Nephropathy.2019Journal of autoimmunity
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy即将招募NCT07535138牵头方(推断)早期I期2026-05 启动
  2. Fecal Microbiota Transplantation for Refractory IgA Nephropathy状态不明NCT03633864牵头方(推断)II期2017-11 启动
  3. Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN正在招募NCT07390123研究中心III期2026-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

西安有 1 家医院列在戈谢病下全国有 40 家医院列在戈谢病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。

这些数字背后的记录
论文中的科室病理/检验科
中文论文(未计入)1
  1. [Clinicopathological study of Gaucher disease].2022Zhonghua bing li xue za zhi = Chinese journal of pathology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

尼曼-匹克病 C 型

Niemann–Pick disease type C

2021–2025 年中国大陆作者发表的 16 篇尼曼-匹克病 C 型 PubMed 英文论文中,这家医院牵头了 1 篇,占 6.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

西安有 1 家医院列在尼曼-匹克病 C 型下全国有 15 家医院列在尼曼-匹克病 C 型下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尼曼-匹克病 C 型开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 17 篇,占 5.7%。

牵头论文
17
2021–2025 年
牵头试验
13
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 5520232024: 5520242025: 442025

西安有 4 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
    分期
    III期
    开始
    2025-12
    登记号
    NCT07296458

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 1 家列出的医院为研究中心广州、西安

  2. 正在招募
    Fenofibrate in Primary Biliary Cholangitis: a Real World Study
    分期
    III期
    开始
    2024-01
    登记号
    NCT06755151

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院西安

  3. 正在招募
    Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
    分期
    III期
    开始
    2024-01
    登记号
    NCT06755541

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院西安

  4. 正在招募
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    分期
    II/III期
    开始
    2023-02
    登记号
    NCT05749822

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 11 家列出的医院为研究中心北京、南京、天津、广州、延安、成都、昆明、沈阳、西安、郑州、长沙

  5. 正在招募
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    分期
    III期
    开始
    2023-02
    登记号
    NCT05751967

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 6 家列出的医院为研究中心兰州、南京、天津、广州、成都、沈阳、西安

  6. 正在招募
    Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)
    分期
    II/III期
    开始
    2017-04
    登记号
    NCT06365424

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院西安

  7. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科风湿免疫科儿科病理/检验科
牵头的论文17
  1. The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine.2025Clinical reviews in allergy & immunology
  2. The prognostic value of anti-gp210 and anti-centromere antibodies in patients with primary biliary cholangitis: Enhancing the prognostic utility on the GLOBE scoring system.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  3. Risk stratification for patients with primary biliary cholangitis: early versus advanced-stage or non-cirrhosis versus cirrhosis?2025Hepatology international
  4. Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment.2025Hepatology international
  5. Hypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary Cholangitis.2024Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  6. Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria.2024Hepatology international
  7. Differences in the perceptions of patients with primary biliary cholangitis and physicians from various hospital departments: An online survey.2024Journal of digestive diseases
  8. Innate lymphoid cell subsets in the pathogenesis of primary biliary cholangitis.2024Journal of gastroenterology and hepatology
  9. Dissecting causal relationships between primary biliary cholangitis and extrahepatic autoimmune diseases based on Mendelian randomization.2024Scientific reports
  10. Integrative bioinformatics analysis and experimental validation of key biomarkers for risk stratification in primary biliary cholangitis.2023Arthritis research & therapy
  11. Laboratory risk factors for coexistent primary biliary cholangitis in patients with Sjögren's syndrome: a retrospective study.2023BMC gastroenterology
  12. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.2023Gastroenterologia y hepatologia
  13. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.2023Hepatology internationalRCT
  14. Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial.2023The American journal of gastroenterologyRCT
  15. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.2022Hepatology communications
  16. Primary biliary cholangitis: personalized medicine for optimal therapeutic opportunities.2022Science bulletin
  17. Decreased infiltration of CD4+ Th1 cells indicates a good response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis.2021Pathology, research and practice
中文论文(未计入)4
  1. [Progress in diagnosis and treatment of primary biliary cholangitis].2025Zhonghua nei ke za zhi
  2. [Progresses and hot spots of primary biliary cholangitis in the past decade].2024Zhonghua nei ke za zhi
  3. [Primary biliary cholangitis in a child].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
  4. [Research progress of osteoporosis in primary biliary cholangitis].2022Zhonghua nei ke za zhi
早期论文(2016–2020 年)6
  1. A nomogram based on pretreatment clinical parameters for the prediction of inadequate biochemical response in primary biliary cholangitis.2020Journal of clinical laboratory analysis
  2. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  3. [Study the role of lysosome-associated membrane protein type 2A for immune-mediated liver injury of primary biliary cholangitis].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  4. [Screening of familial primary biliary cholangitis and research on low-frequency mutations by whole-exome sequencing].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  5. [Primary biliary cholangitis and bile acid metabolism].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  6. [An interpretation of 2017 EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)17
  1. FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy正在招募NCT07296458牵头方III期2025-12 启动
  2. Fenofibrate in Primary Biliary Cholangitis: a Real World Study正在招募NCT06755151牵头方III期2024-01 启动
  3. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study正在招募NCT06755541牵头方III期2024-01 启动
  4. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis正在招募NCT05749822牵头方II/III期2023-02 启动
  5. Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis正在招募NCT05751967牵头方III期2023-02 启动
  6. Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)正在招募NCT06365424牵头方II/III期2017-04 启动
  7. Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)进行中,不再招募NCT07104201牵头方早期I期2025-03 启动
  8. Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis状态不明NCT03668145牵头方不分期2017-11 启动
  9. Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis状态不明NCT02916290牵头方III期2016-01 启动
  10. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis已完成NCT02823353牵头方III期2016-04 启动
  11. Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid正在招募NCT02823366牵头方III期2016-01 启动
  12. Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid状态不明NCT02916641牵头方III期2016-01 启动
  13. A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis已完成NCT06591455牵头方(推断)早期I期2024-09 启动
  14. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动
  15. A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics邀请入组NCT06591468研究中心II/III期2024-10 启动
  16. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis进行中,不再招募NCT06174402研究中心II/III期2023-08 启动
  17. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

西安有 4 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

西安有 2 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride已完成NCT03333265牵头方II/III期2017-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

空军军医大学西京医院

Xijing Hospital

西安

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Xijing Hospital of Digestive Diseases; Xijing Hospital of Digestive Disease; XiJing Hospital; Xijing Hospital of The Fourth Military Medical University; Xijing Hospital Fourth Military Medical University; Xijing Hospital Affiliated to Fourth Military Medical University; Air Force Medical University Xijing Hospital; Xijing Hospital of Air Force Medical University

提出更正下载数据